Health Boards
Xeljanz (Tofacitinib) is sometimes precribed to treat psoriatic arthritis.
The UK have issued a drug safety update for it's use:
Source: gov.uk
The UK have issued a drug safety update for it's use:
Quote:
Tofacitinib: New measures to minimise risk of venous thromboembolism and of serious and fatal infections.
Caution should be used in patients with known risk factors for venous thromboembolism in addition to the underlying disease. Patients older than 65 years of age are at an increased risk of serious infections and should be treated with tofacitinib only if there is no alternative treatment.
Source: gov.uk
